These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11391160)

  • 21. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.
    Yang X; Wyatt R; Sodroski J
    J Virol; 2001 Feb; 75(3):1165-71. PubMed ID: 11152489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of virus-like Semliki Forest virus replicon particles expressing Indian HIV-1C gag, env and polRT genes.
    Ajbani SP; Velhal SM; Kadam RB; Patel VV; Lundstrom K; Bandivdekar AH
    Immunol Lett; 2017 Oct; 190():221-232. PubMed ID: 28851629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
    Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
    AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
    Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
    Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
    Rose NF; Roberts A; Buonocore L; Rose JK
    J Virol; 2000 Dec; 74(23):10903-10. PubMed ID: 11069984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
    Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.
    Emmer KL; Wieczorek L; Tuyishime S; Molnar S; Polonis VR; Ertl HC
    AIDS; 2016 Oct; 30(16):2405-2414. PubMed ID: 27525550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human studies in the development of human immunodeficiency virus vaccines.
    Dolin R
    J Infect Dis; 1995 Nov; 172(5):1175-83. PubMed ID: 7594651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.
    Buonaguro L; Racioppi L; Tornesello ML; Arra C; Visciano ML; Biryahwaho B; Sempala SD; Giraldo G; Buonaguro FM
    Antiviral Res; 2002 Jun; 54(3):189-201. PubMed ID: 12062391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Mandava M; Berman PW; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):921-30. PubMed ID: 10408729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
    Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Mascola JR; Snyder SW; Weislow OS; Belay SM; Belshe RB; Schwartz DH; Clements ML; Dolin R; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Walker MC; Wagner KF; McNeil JG; McCutchan FE; Burke DS
    J Infect Dis; 1996 Feb; 173(2):340-8. PubMed ID: 8568294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization of rabbits with a modified vaccinia Ankara recombinant virus bearing the HIV envelope antigen on its outer membrane.
    Barchichat S; Katz E
    Virus Res; 2002 Dec; 90(1-2):243-51. PubMed ID: 12457978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.
    Gómez-Román VR; Florese RH; Peng B; Montefiori DC; Kalyanaraman VS; Venzon D; Srivastava I; Barnett SW; Robert-Guroff M
    J Acquir Immune Defic Syndr; 2006 Nov; 43(3):270-7. PubMed ID: 16940858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.
    Berglund P; Quesada-Rolander M; Putkonen P; Biberfeld G; Thorstensson R; Liljeström P
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1487-95. PubMed ID: 9390747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.